Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.

about

Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.

Item

http://www.wikidata.org/entity/Q47633998

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cell Signaling Model Connects ...... n Multiple Myeloma Xenografts.

@en

Cell Signaling Model Connects ...... n Multiple Myeloma Xenografts.

@nl

type

Item

label

Cell Signaling Model Connects ...... n Multiple Myeloma Xenografts.

@en

Cell Signaling Model Connects ...... n Multiple Myeloma Xenografts.

@nl

prefLabel

Cell Signaling Model Connects ...... n Multiple Myeloma Xenografts.

@en

Cell Signaling Model Connects ...... n Multiple Myeloma Xenografts.

@nl

P1476

Cell Signaling Model Connects ...... n Multiple Myeloma Xenografts.

@en

P2093

Charvi Nanavati

http://www.w3.org/2001/XMLSchema#string

Donald E Mager

http://www.w3.org/2001/XMLSchema#string

Donna Ruszaj

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor

The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation

Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies.

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Apoptosis of multiple myeloma.

Pharmacodynamic modeling of time-dependent transduction systems.

Comparison of four basic models of indirect pharmacodynamic responses

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.

P304

756-764

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12246

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29045072

http://www.w3.org/2001/XMLSchema#string

P921

xenograft

P932

5702904

http://www.w3.org/2001/XMLSchema#string